Is the world ready for the STICH 3.0 trial?

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Coronary artery disease (CAD) is a leading cause of heart failure.
• Ischemic left ventricular systolic dysfunction (iLVSD) significantly worsens outcomes after revascularization.
• Current trials inadequately represent patients with iLVSD.

Purpose of the Study:

• To review coronary revascularization options for patients with iLVSD.
• To emphasize the need for randomized controlled trials (RCTs) in this population.
• To discuss the current evidence comparing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in iLVSD.

Main Methods:

• Review of existing literature and network meta-analyses of observational studies.
• Analysis of outcomes data comparing PCI and CABG in patients with iLVSD.
• Identification of knowledge gaps and future research directions.

Main Results:

• Observational studies suggest CABG may offer better survival rates than PCI in iLVSD patients.
• PCI has been associated with higher rates of mortality, cardiac death, and myocardial infarction.
• Advances in PCI technology are improving outcomes, but direct comparative evidence is lacking.

Conclusions:

• The optimal revascularization strategy for iLVSD remains uncertain.
• Observational data favors CABG, but RCT evidence is absent.
• New trials, like the Surgical Treatment for Ischemic Heart Failure 3.0, aim to resolve this clinical equipoise.